Associated Papers
Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity.
Kwon JJ et al.
Biorxiv : the Preprint Server for Biology, 2024
39484452 (PubMed )
Supplement: media-2.zip › Extended_Data_Tables › Extended_Data_Table_1.xlsx › KRAS_GOF_DMS_Screen
Source, co-occurrence, and prognostic value of PTEN mutations or loss in colorectal cancer.
Serebriiskii IG et al.
Npj Genomic Medicine, 2023
38001126 (PubMed )
Supplement: 41525_2023_384_MOESM1_ESM.xlsx › Table_S6
Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants.
Khan I et al.
Cell Reports, 2022
Incidence and PD-L1 Expression of MET 14 Skipping in Chinese Population: A Non-Selective NSCLC Cohort Study Using RNA-Based Sequencing.
Xu Z et al.
Oncotargets and Therapy, 2020
COSMIC: High-Resolution Cancer Genetics Using the Catalogue of Somatic Mutations in Cancer.
Forbes SA et al.
Current Protocols in Human Genetics, 2016
Rectal cancer profiling identifies distinct subtypes in India based on age at onset, genetic, epigenetic and clinicopathological characteristics.
Laskar RS et al.
Molecular Carcinogenesis, 2015
A distinct class of dominant negative Ras mutants: cytosolic GTP-bound Ras effector domain mutants that inhibit Ras signaling and transformation and enhance cell adhesion.
Fiordalisi JJ et al.
The Journal of Biological Chemistry, 2002
Select a paper to view details